Neonatal diabetes with Kir 6,2 mutation on glibenclamide therapy
Poovazhagi V, Muralidharan PS, Parivathini S
The Diabetic clinic, Institute of Child Health and Hospital for Children, Egmore, Chennai
Abstract

Genetic studies in neonatal diabetes can drastically change the therapy lifelong. An 82 days infant with diabetes mellitus on insulin was diagnosed with mutation of the KCNJ11 gene encoding kir 6.2 and was successfully switched over to oral glibenclamide. Child is maintaining euglycemia and is off insulin therapy.
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.